HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $90.00 price target on the biotechnology company’s stock. Several other equities research analysts also recently commented on VKTX. JPMorgan Chase & Co. initiated coverage on Viking […]

Marathon Digital (NASDAQ:MARA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $27.00 target price on the business services provider’s stock. HC Wainwright’s price objective points to a potential upside of 67.91% from the stock’s […]

HC Wainwright reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $90.00 target price on the biotechnology company’s stock. A number of other brokerages also recently commented on VKTX. JPMorgan Chase & Co. initiated coverage on […]

HC Wainwright reaffirmed their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the specialty pharmaceutical company’s stock. Other research analysts also recently issued research reports about the stock. Needham & Company […]

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 219.77% from the […]

HC Wainwright reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report report published on Monday, Benzinga reports. They currently have a $64.00 price objective on the stock. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2024 earnings at ($0.77) EPS, Q4 2024 earnings at ($0.78) EPS, […]